Replimune Group, Inc. (NASDAQ:REPL) Insider Konstantinos Xynos Sells 7,246 Shares

Replimune Group, Inc. (NASDAQ:REPL) insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Replimune Group Stock Up 2.6 %

REPL opened at $11.23 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The company’s 50 day simple moving average is $11.48 and its two-hundred day simple moving average is $9.64. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $12.97.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. Research analysts anticipate that Replimune Group, Inc. will post -3.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Roth Mkm started coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research report on Tuesday, November 12th. Finally, Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Replimune Group presently has an average rating of “Buy” and a consensus price target of $16.80.

Institutional Trading of Replimune Group

Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in Replimune Group in the first quarter valued at $147,000. Russell Investments Group Ltd. acquired a new position in Replimune Group in the first quarter valued at about $140,000. Vanguard Group Inc. boosted its stake in Replimune Group by 1.2% during the first quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock worth $22,634,000 after buying an additional 32,555 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Replimune Group during the first quarter valued at about $927,000. Finally, Clearbridge Investments LLC lifted its holdings in shares of Replimune Group by 2.7% in the 1st quarter. Clearbridge Investments LLC now owns 277,969 shares of the company’s stock worth $2,271,000 after acquiring an additional 7,274 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.